Board of Directors
R&D Director
Matthew Wilcox
•PhD in Human Physiology
gNewcastle University
•6 years postdoctoral experience
Managing and Financial Director
Juliane Klein
• MBA, FCA
• Chartered accountant: PWC
• Management consultancy:
Reed Cons.
Marketing Director
Laura Pascoe
• MBA Business and Marketing
gExeter University
• 5 years Marketing at Unilever
gLondon
Operations Director
Alessandra S. Dantas
• MD University of Sao Paulo, MBA
gHarvard University
• 8 years Head of Department of Clinical
gScience
Research and Development
•
•
•
•
•
•
Tablet that you take before your main meal
Forms a gel in the stomach
Gives the feeling fullness
Weight loss
Reduction in bile re-uptake
Therefore lowers cholesterol
Intellectual Property Time Line
2005
2006
University
File Patent
University
File for PCT
2007
2008
UK Patent
Granted
Prosecute in
US, Canada,
Europe,
Japan, China
and India
Pipe Line
• Product Line
▫ Different Vehicles for Administration
▫ Different Flavours
▫ Different Doses
• Product Range
▫ Diabetes prevention and control
▫ Specific cholesterol lowering
▫ Inhibition of Dietary Enzymes
Marketing and Sales Strategy
Overview, Drivers & Competition
Currently trying to lose weight
Overweight individuals UK
Men
Women
• Food and supplement market £75 billion in Europe
Men
Women
Source: 200 16+ males and females
interviewed Newcastle and London
Sales Strategy
• 1 Million trial packs
• Loss leader- viral marketing
• Letters of intent
Operations
Operations - Production and
Distribution Strategies
Macclesfield
Nottingham
INDIA
Operations Structure of Fybre ltd.
Operations Director
Warehouse Liaising
Outsourced Services
FastEffects Designs
Strain-Keville Solicitors
WebZing
Sidhartha, Vergesi
Rimanshu-India
TFL- Macclesfield
Eddie Stobart ltd.
Timeline and Milestones for Production of 1
million sample packets of Accelerol®
Months
1
Buy in & shipment of raw material for WeightWatchers trial
1-3
Accelerol® pressing and distribution to WeightWatchers trial
4-7
Stock piling and initial distribution to Boots, intensive advertising
8
Accelerol ® available to purchase from Boots nationwide
Financial Projections
Company Equity Share
10%
22.5%
Your Investment
Personal investment:
£20,000/Director
22.5%
£80,000 for patent
applications in Europe,
USA, Canada, Japan,
China, India
Company set up (Ltd.)
and University buy BBSRC
out: £80,000 (pref. Entrepreneur
shares) + 10%
Fellowship
company
2007
2008
Start of large scale
production and
product launch UK
22.5%
22.5%
Possible exit
through IPO or
Trade Sale
Start of product trial
through health clubs,
Quality assurance
1NE Research and
Development
Grant £100,000
2009
Initial Investment:
£800,000 for 40% equity
2010
Closing
negotiations for
whole sale to
Danone, Unilever,
Nestle
2011
2012
2013
Financial Projections
Production cost/unit: £0.50
Unit price whole sale: £2.50
Company value after 5 years: £31 M
Year 1
Year 2
Year 3
Year 4
Year 5
£795.000
£7.7M
£12.6M
£17.5M
£28.5M
Thank You
Sponsored by:
Balance Sheet Fybre ltd..xls
Cash Flow Fybre ltd.xls